NCT05234177 Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
| NCT ID | NCT05234177 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tempus AI |
| Condition | Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2022-06-21 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2022-06-21 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
Eligibility Criteria
Inclusion Criteria: * Known or suspected colorectal adenocarcinoma (Stage I to IVA disease) * Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent. * 18 years old or older * Willing and able to provide informed consent * Willing to have additional blood samples collected during routine surveillance visits Exclusion Criteria: * Not willing to have additional blood samples collected * Pathology that is not consistent with colorectal adenocarcinoma
Contact & Investigator
Kristiyana Kaneva, MD, MS
PRINCIPAL INVESTIGATOR
Tempus AI, Inc.
Frequently Asked Questions
Who can join the NCT05234177 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05234177 currently recruiting?
Yes, NCT05234177 is actively recruiting participants. Contact the research team at gemini-crc@tempus.com for enrollment information.
Where is the NCT05234177 trial being conducted?
This trial is being conducted at Fort Smith, United States, Fountain Valley, United States, Bethesda, United States, Joplin, United States and 11 additional locations.
Who is sponsoring the NCT05234177 clinical trial?
NCT05234177 is sponsored by Tempus AI. The principal investigator is Kristiyana Kaneva, MD, MS at Tempus AI, Inc.. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.